Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Meta Analysis Comparative Study
Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Luteinizing hormone-releasing hormone (LHRH) agonists represent one of the main cost factors in the management of patients with metastatic prostate cancer. We compared the cost-effectiveness of the five different 3-month formulations of LHRH agonists currently available for advanced prostate cancer in Italy, because these differ both in their capacity to suppress testosterone and in their acquisition costs. ⋯ Based on modelling with meta-analysis of comparative survival data, leuprorelin 22.5 mg was the most cost-effective treatment of the available depot formulation LHRH agonists.